Market Place
Sourcing Support
NDMA issue persists as 2 more companies recall Nizatidine-based products
04 Jan 2022 //
KOREABIOMED
Enforcement Report - Week of May 6, 2020
06 May 2020 //
FDA
Health Canada Issues Recall of Pendopharm Division of Pharmascience`s AXID
04 May 2020 //
HEALTH CANADA
Amneal recalls ulcer drug on NDMA contamination fears
17 Apr 2020 //
FIERCE PHARMA
Enforcement Report - Week of January 29, 2020
29 Jan 2020 //
FDA
Mylan recalls close-to-expiration nizatidine capsules over NDMA impurity
13 Jan 2020 //
IN-PHARMATECHNOLOGIST
US-based Mylan Pharma initiates voluntary recall of Nizatidine Solara Active
09 Jan 2020 //
THEHINDUBUSINESSLINE
Sanofi CEO Paul Hudson offers up advice for digitally ambitious pharmas
09 Jan 2020 //
FIERCE PHARMA
Solara Active Pharma to conduct internal probe on Nizatidine API
08 Jan 2020 //
ECONOMIC TIMES
Mylan Initiates Voluntary Nationwide Recall of Three Lots of Nizatidine Capsule
08 Jan 2020 //
PR NEWSWIRE
Mylan Initiates Voluntary Nationwide Recall of Three Lots of Nizatidine Capsule
07 Jan 2020 //
PR NEWSWIRE
Mylan Initiates Voluntary Nationwide Recall of Three Lots of Nizatidine Capsule
07 Jan 2020 //
PR NEWSWIRE
Solara Active Pharma Sciences update on Ranitidine HCL & Nizatidine API
25 Nov 2019 //
BUSINESS-STANDARD
Solara Active Pharma Sciences update on Ranitidine Hydrochloride & Nizatidine API
04 Nov 2019 //
BUSINESS-STANDARD
FDA Explains Levels of Impurity Found in Recalled Heartburn Drugs
01 Nov 2019 //
RAPS
USFDA inspects Solara Active Pharma`s Cuddalore facility
08 Jul 2019 //
BUSINESS LINE
ViiV Healthcare Announces PhII Study Results for First Two Drug
23 Feb 2016 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.